نتائج البحث

1

دورية أكاديمية

OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group.

المؤلفون: Tesileanu, C M S, French, P J, Sanson, M, Brandes, A A, Wick, W, Clement, P M, Kros, J M, Gorlia, T, Golfinopoulos, V, Bent, M J van den

المصدر: Neuro-Oncology; 2021 Supplement, Vol. 23, pii6-ii7, 2p

النص الكامل

2

دورية أكاديمية

PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.

المؤلفون: Coomans, M, Dirven, L, Aaronson, N, Baumert, B, Bent, M van den, Bottomley, A, Brandes, A, Chinot, O, Coens, C, Gorlia, T, Herrlinger, U, Keime-Guibert, F, Malmström, A, Martinelli, F, Stupp, R, Talacchi, A, Wick, W, Reijneveld, J, Taphoorn, M

المصدر: Neuro-Oncology; 2021 Supplement, Vol. 23, pii2-ii3, 2p

النص الكامل

3

دورية أكاديمية

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.

المؤلفون: Sköld, K.¹, Gorlia, T.², Pellettieri, L.^1,3, Giusti, V.^1,4, H.-Stenstam, B.⁵, Hopewell, J. W.⁶ john.hopewell@gtc.ox.ac.uk

المصدر: British Journal of Radiology. Jul2010, Vol. 83 Issue 991, p596-603. 8p. 6 Charts, 2 Graphs.

مصطلحات موضوعية: *BORON-neutron capture therapy, *GLIOBLASTOMA multiforme treatment, *INFUSION therapy, *FRUCTOSE, *RADIOTHERAPY, *ADJUVANT treatment of cancer, *SALVAGE therapy

4

دورية أكاديمية

OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials.

المؤلفون: Furtner, J, Weller, M, Weber, M, Gorlia, T, Nabors, B, Reardon, D, Tonn, J, Stupp, R, Preusser, M

المصدر: Neuro-Oncology; 2021 Supplement, Vol. 23, pii7-ii7, 1p

النص الكامل

5

دورية أكاديمية

P11.08 Defining EGFR amplification status for clinical trial inclusion.

المؤلفون: French, P, Eoli, M, Sepulveda, J, Heer, I de, Kros, J M, Walenkamp, A, Frenel, J, Franceschi, E, Clement, P, Weller, M, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, Bent, M van den

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii43-iii44, 2p

النص الكامل

6

دورية أكاديمية

OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM).

المؤلفون: Coomans, M, Dirven, L, Bottomley, A, Bent, M van den, Sloan, J, Stupp, R, Weller, M, Reijneveld, J C, Taphoorn, M, Aaronson, N, Baumert, B G, Brandes, A A, Chinot, O, Coens, C, Gorlia, T, Herrlinger, U, Keime-Guibert, F, Malmström, A, Martinelli, F, Talacchi, A

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii14-iii15, 2p

النص الكامل

7

دورية أكاديمية

PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).

المؤلفون: Preusser, M, Silvani, A, Rhun, E Le, Soffietti, R, Lombardi, G, Sepulveda, J, Brandal, P, Beaney, R, Bonneville-Levard, A, Lorgis, V, Bromberg, J, Erridge, S, Cameron, A, Marosi, C, Golfinopoulos, V, Gorlia, T, Weller, M, Wick, W

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii2-iii3, 2p

النص الكامل

8

دورية أكاديمية

P14.54 Association of EGFR Expression and Copy Number with Outcome in Depatux-m (ABT-414) Randomized Phase II Study of the EORTC Brain Tumor Group.

المؤلفون: Bent, M J van den, Gorlia, T, Sun, Y, Kular, R, Looman, J, Bain, E E, Robberts-Rapp, L, Ansell, P J, Golfinopoulos, V, French, P

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii79-iii79, 1p

النص الكامل

9

دورية أكاديمية

P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial.

المؤلفون: Furtner, J, Genbrugge, E, Gorlia, T, Bendszus, M, Nowosielski, M, Golfinopoulos, V, Weller, M, Bent, M J van den, Wick, W, Preusser, M

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii76-iii76, 1p

النص الكامل

10

دورية أكاديمية

P14.124 EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

المؤلفون: Roth, P, Reijneveld, J, Gorlia, T, Dhermain, F, Vos, F De, Vanlancker, M, O'Callaghan, C, Rhun, E Le, Bent, M van den, Mason, W, Weller, M

المصدر: Neuro-Oncology; 2019 Supplement, Vol. 21, piii98-iii98, 1p

النص الكامل

تنقيح النتائج